Showing results (251-260 of 976) with videos related to

Sort By:
Pageof 98
NPJ Breast Cancer|June 19, 2020
Skeletal muscle reprogramming by breast cancer regardless of treatment history or tumor molecular subtypeHannah E Wilson, David A Stanton, Cortney Montgomery, et al.
NPJ Breast Cancer|January 14, 2022
The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situDaniela Nachmanson, Adam Officer, Hidetoshi Mori, et al.
NPJ Breast Cancer|January 18, 2022
Value of the loss of heterozygosity to BRCA1 variant classificationElizabeth Santana Dos Santos, Amanda B Spurdle, Dirce M Carraro, et al.
NPJ Breast Cancer|December 22, 2021
The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database StudyMary Kathryn Abel, Amy M Shui, Michelle Melisko, et al.
NPJ Breast Cancer|September 20, 2022
Mechanostimulation of breast myoepithelial cells induces functional changes associated with DCIS progression to invasionMary-Kate Hayward, Michael D Allen, Jennifer J Gomm, et al.
NPJ Breast Cancer|September 18, 2022
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINESibylle Loibl, Chiun-Sheng Huang, Max S Mano, et al.
NPJ Breast Cancer|December 10, 2021
Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testingMelissa C Southey, James G Dowty, Moeen Riaz, et al.
NPJ Breast Cancer|January 11, 2022
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancerLuca Gianni, Marco Colleoni, Giancarlo Bisagni, et al.
NPJ Breast Cancer|January 11, 2022
Endoplasmic reticulum stress inhibits AR expression via the PERK/eIF2α/ATF4 pathway in luminal androgen receptor triple-negative breast cancer and prostate cancerXiaoli Li, Duanfang Zhou, Yongqing Cai, et al.
NPJ Breast Cancer|January 19, 2022
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBCCharlotte Rypens, François Bertucci, Pascal Finetti, et al.
Pageof 98